Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ra Pharmaceuticals | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in participants with ALS.
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683.
Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.
If a participant is randomized to Regimen A - Zilucoplan, the participant will complete a screening visit to assess additional Regimen A eligibility criteria. Once Regimen A eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active zilucoplan or matching placebo.
Regimen A will enroll by invitation, as participants may not choose to enroll in Regimen A. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen A.
For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Zilucoplan | Experimental | Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily |
|
| Matching Placebo | Placebo Comparator | Administration: Subcutaneous injection Dosage: Daily subcutaneous injection |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Zilucoplan | Drug | Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| Disease Progression as Assessed by the ALSFRS-R Total Score | Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function. | Baseline through 24 Weeks |
| Mortality Event Rate | Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times. | Baseline through 24 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Respiratory Function | Change in respiratory function as assessed by slow vital capacity (SVC). | Baseline and 24 Weeks |
| Muscle Strength | Change in muscle strength as measured isometrically using hand-held dynamometry (HHD). |
Not provided
Inclusion Criteria:
The following inclusion criterion is in addition to the inclusion criteria specified in the Master Protocol (NCT NCT04297683).
Exclusion Criteria:
The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Merit Cudkowicz | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Healey Center for ALS at Mass General | Boston | Massachusetts | 02114 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Zilucoplan | Drug: Zilucoplan Administration: Subcutaneous injection Dosage: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight |
| FG001 | Matching Placebo | Administration: Subcutaneous injection Dosage: Daily subcutaneous injection |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Baseline Analysis Population includes only placebo participants from the Regimen A Efficacy Regimen Only (ERO) sample; shared placebo participants from other regimens are not included in the Baseline Analysis Population.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Zilucoplan | Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily |
| BG001 | Matching Placebo | Administration: Subcutaneous injection Dosage: Daily subcutaneous injection |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Disease Progression as Assessed by the ALSFRS-R Total Score | Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function. | Outcome measure data was analyzed using the Full Analysis Set, which included shared placebo from other regimens, as pre-specified in the Regimen Statistical Analysis Plan. Regimen B Verdiperstat (NCT04436510), Regimen C CNM-Au8 (NCT04414345), and Regimen D Pridopidine (NCT04615923) contributed placebo participants into the shared placebo cohort used for analysis. | Posted | Mean | Standard Deviation | ALSFRS-R total score points per month | Baseline through 24 Weeks |
|
Up to 35 weeks after participant signed Master Protocol consent.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Zilucoplan | Drug: Zilucoplan Administration: Subcutaneous injection Dosage: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight Zilucoplan: Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Muscular weakness | Nervous system disorders | MedDRA 23.0 | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Healey Center for ALS Project Management | Healey Center for ALS at Massachusetts General Hospital | 833-425-8257 (HALT ALS) | healeyalsplatform@mgh.harvard.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 15, 2021 | Apr 4, 2023 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jul 22, 2022 | Apr 4, 2023 | SAP_001.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000690 | Amyotrophic Lateral Sclerosis |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| C000719268 | zilucoplan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Matching Placebo | Drug | Drug: Matching Placebo Administration: Subcutaneous injection Dosage: Daily subcutaneous injection |
|
| Baseline and 24 Weeks |
| Number of Participants That Experienced Death or Death Equivalent | The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row. | Baseline through 24 Weeks |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| El Escorial Diagnosis | Count of Participants | Participants |
|
| Time Since Symptom onset at Baseline | Mean | Standard Deviation | months |
|
| Delay in ALS Symptom Onset and Diagnosis | Mean | Standard Deviation | months |
|
| ALS Onset Location | Count of Participants | Participants |
|
| Baseline Edaravone Use | Count of Participants | Participants |
|
| Baseline Riluzole Use | Count of Participants | Participants |
|
| ALSFRS-R Total Score | The ALS Functional Rating Scare-Revised (ALSFRS-R) measures 12 aspects of physical function. Each of the 12 questions assessing distinct functional ability is scored from 4(normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function. | Mean | Standard Deviation | scores on a scale |
|
| Change in ALSFRS-R prior to Baseline | The ALS Functional Rating Scare-Revised (ALSFRS-R) measures 12 aspects of physical function. Each of the 12 questions assessing distinct functional ability is scored from 4(normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Baseline decline in ALSFRS-R was calculated as 48 minus the ALSFRS-R total score at Baseline. The difference between 48 and ALSFRS-R total score at Baseline is divided by the number of months between onset of weakness due to ALS and the date of Baseline. A higher number indicates greater decline. | Mean | Standard Deviation | points per month |
|
| SVC | Number analyzed in row differs from overall number due to missing data. | Mean | Standard Deviation | percent predicted |
|
| Kings Stage | The King's ALS Clinical Staging System is a 4-level ordinal scale with the first three levels indicating the number (1, 2, or 3) of distinct central nervous system regions (bulbar, upper limb, and lower limb) with neuromuscular dysfunction. Level 4a indicates nutritional failure and level 4b indicates respiratory failure. Higher scores indicate a worse disease state. | Count of Participants | Participants |
|
| Weight | Mean | Standard Deviation | kg |
|
| Body Mass Index | Mean | Standard Deviation | kg/m^2 |
|
| Serum Creatinine Concentration | Mean | Standard Deviation | mg/dL |
|
| Neurofilament Light (NfL) Protein in Serum | Number analyzed in row differs from overall number due to missing data. | Mean | Standard Deviation | ng/L |
|
Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily |
| OG001 | Matching Placebo | Administration: Subcutaneous injection Dosage: Daily subcutaneous injection |
|
|
|
| Primary | Mortality Event Rate | Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times. | Outcome measure data was analyzed using the Full Analysis Set, which included shared placebo from other regimens, as pre-specified in the Regimen Statistical Analysis Plan. Regimen B Verdiperstat (NCT04436510), Regimen C CNM-Au8 (NCT04414345), and Regimen D Pridopidine (NCT04615923) contributed placebo participants into the shared placebo cohort used for analysis. | Posted | Mean | Standard Deviation | events per month | Baseline through 24 Weeks |
|
|
|
| Secondary | Respiratory Function | Change in respiratory function as assessed by slow vital capacity (SVC). | Outcome measure data was analyzed using the Full Analysis Set, which included shared placebo from other regimens, as pre-specified in the Regimen Statistical Analysis Plan. Regimen B Verdiperstat (NCT04436510), Regimen C CNM-Au8 (NCT04414345), and Regimen D Pridopidine (NCT04615923) contributed placebo participants into the shared placebo cohort used for analysis. | Posted | Least Squares Mean | Standard Error | percent change | Baseline and 24 Weeks |
|
|
|
|
| Secondary | Muscle Strength | Change in muscle strength as measured isometrically using hand-held dynamometry (HHD). | Outcome measure data was analyzed using the Full Analysis Set, which included shared placebo from other regimens, as pre-specified in the Regimen Statistical Analysis Plan. Regimen B Verdiperstat (NCT04436510), Regimen C CNM-Au8 (NCT04414345), and Regimen D Pridopidine (NCT04615923) contributed placebo participants into the shared placebo cohort used for analysis. | Posted | Least Squares Mean | Standard Error | percent change | Baseline and 24 Weeks |
|
|
|
|
| Secondary | Number of Participants That Experienced Death or Death Equivalent | The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row. | Outcome measure data was analyzed using the Full Analysis Set, which included shared placebo from other regimens, as pre-specified in the Regimen Statistical Analysis Plan. Regimen B Verdiperstat (NCT04436510), Regimen C CNM-Au8 (NCT04414345), and Regimen D Pridopidine (NCT04615923) contributed placebo participants into the shared placebo cohort used for analysis. Two placebo participants from FAS were not at risk: 1 initiated PAV before baseline, 1 had 0 days of follow-up. | Posted | Count of Participants | Participants | Baseline through 24 Weeks |
|
|
|
|
| 5 |
| 122 |
| 25 |
| 122 |
| 115 |
| 122 |
| EG001 | Matching Placebo | Administration: Subcutaneous injection Dosage: Daily subcutaneous injection Matching Placebo: Drug: Matching Placebo Administration: Subcutaneous injection Dosage: Daily subcutaneous injection | 2 | 40 | 3 | 40 | 37 | 40 |
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Increased upper airway secretion | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Dysphagia | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Faecaloma | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Pancreatitis | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Pneumoperitoneum | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| COVID-19 | Infections and infestations | MedDRA 23.0 | Non-systematic Assessment |
|
| COVID-19 pneumonia | Infections and infestations | MedDRA 23.0 | Non-systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA 23.0 | Non-systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA 23.0 | Non-systematic Assessment |
|
| Cardiac arrest | Cardiac disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Cardiac failure congestive | Cardiac disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Supraventricular tachycardia | Cardiac disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Generalised oedema | General disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Chest pain | General disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Sudden death | General disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Oesophageal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 23.0 | Non-systematic Assessment |
|
| Device malfunction | Product Issues | MedDRA 23.0 | Non-systematic Assessment |
|
| Deep vein thrombosis | Vascular disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Neuromyopathy | Nervous system disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Dysarthria | Nervous system disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Tension headache | Nervous system disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA 23.0 | Non-systematic Assessment |
|
| Injection site bruising | Injury, poisoning and procedural complications | MedDRA 23.0 | Non-systematic Assessment |
|
| Injection site pain | Injury, poisoning and procedural complications | MedDRA 23.0 | Non-systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | MedDRA 23.0 | Non-systematic Assessment |
|
| Injection site reaction | Injury, poisoning and procedural complications | MedDRA 23.0 | Non-systematic Assessment |
|
| Traumatic haematoma | Injury, poisoning and procedural complications | MedDRA 23.0 | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Dysphagia | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Salivary hypersecretion | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Fatigue | General disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Oedema peripheral | General disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Urinary tract infection | Infections and infestations | MedDRA 23.0 | Non-systematic Assessment |
|
| COVID-19 | Infections and infestations | MedDRA 23.0 | Non-systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Anxiety | Psychiatric disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Tinnitus | Ear and labyrinth disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Post-traumatic pain | Injury, poisoning and procedural complications | MedDRA 23.0 | Non-systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 23.0 | Non-systematic Assessment |
|
| Hepatic enzyme increased | Investigations | MedDRA 23.0 | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| D019636 | Neurodegenerative Diseases |
| D057177 | TDP-43 Proteinopathies |
| D009468 | Neuromuscular Diseases |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Clinically Probable ALS - Laboratory Supported |
|
| Clinically Possible ALS |
|
| Multiple |
|
| Respiratory |
|
| 3 Regions with Neuromuscular Dysfunction |
|
| 4a/b Nutritional/Respiratory Failure |
|